Literature DB >> 27252508

The optimal dosing of gemtuzumab ozagamicin: where to go from here?

Theo de Witte1, Sergio Amadori2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27252508      PMCID： PMC5013949          DOI： 10.3324/haematol.2016.145763

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  10 in total

Review 1.  Acute Myeloid Leukemia.

Authors:  Hartmut Döhner; Daniel J Weisdorf; Clara D Bloomfield
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

2.  Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.

Authors:  Richard A Larson; Eric L Sievers; Edward A Stadtmauer; Bob Löwenberg; Elihu H Estey; Hervé Dombret; Matthias Theobald; Dimitris Voliotis; John M Bennett; Maria Richie; Lance H Leopold; Mark S Berger; Matthew L Sherman; Michael R Loken; Jacques J M van Dongen; Irwin D Bernstein; Frederick R Appelbaum
Journal:  Cancer       Date:  2005-10-01       Impact factor: 6.860

3.  Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17).

Authors:  Sergio Amadori; Stefan Suciu; Roberto Stasi; Helmut R Salih; Dominik Selleslag; Petra Muus; Paolo De Fabritiis; Adriano Venditti; Anthony D Ho; Michael Lübbert; Xavier Thomas; Roberto Latagliata; Constantijn J M Halkes; Franca Falzetti; Domenico Magro; José E Guimaraes; Zwi Berneman; Giorgina Specchia; Matthias Karrasch; Paola Fazi; Marco Vignetti; Roel Willemze; Theo de Witte; Jean-Pierre Marie
Journal:  J Clin Oncol       Date:  2013-10-14       Impact factor: 44.544

Review 4.  CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.

Authors:  M L Linenberger
Journal:  Leukemia       Date:  2005-02       Impact factor: 11.528

5.  Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

Authors:  Alan K Burnett; Robert K Hills; Donald Milligan; Lars Kjeldsen; Jonathan Kell; Nigel H Russell; John A L Yin; Ann Hunter; Anthony H Goldstone; Keith Wheatley
Journal:  J Clin Oncol       Date:  2010-12-20       Impact factor: 44.544

6.  Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.

Authors:  Sylvie Castaigne; Cécile Pautas; Christine Terré; Emmanuel Raffoux; Dominique Bordessoule; Jean-Noel Bastie; Ollivier Legrand; Xavier Thomas; Pascal Turlure; Oumedaly Reman; Thierry de Revel; Lauris Gastaud; Noémie de Gunzburg; Nathalie Contentin; Estelle Henry; Jean-Pierre Marolleau; Ahmad Aljijakli; Philippe Rousselot; Pierre Fenaux; Claude Preudhomme; Sylvie Chevret; Hervé Dombret
Journal:  Lancet       Date:  2012-04-05       Impact factor: 79.321

7.  Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells.

Authors:  V H van Der Velden; J G te Marvelde; P G Hoogeveen; I D Bernstein; A B Houtsmuller; M S Berger; J J van Dongen
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

8.  Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics.

Authors:  L M Hinman; P R Hamann; R Wallace; A T Menendez; F E Durr; J Upeslacis
Journal:  Cancer Res       Date:  1993-07-15       Impact factor: 12.701

Review 9.  Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.

Authors:  Robert K Hills; Sylvie Castaigne; Frederick R Appelbaum; Jacques Delaunay; Stephen Petersdorf; Megan Othus; Elihu H Estey; Hervé Dombret; Sylvie Chevret; Norbert Ifrah; Jean-Yves Cahn; Christian Récher; Lucy Chilton; Anthony V Moorman; Alan K Burnett
Journal:  Lancet Oncol       Date:  2014-07-06       Impact factor: 41.316

10.  Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.

Authors:  Alan K Burnett; Nigel H Russell; Robert K Hills; Jonathan Kell; Sylvie Freeman; Lars Kjeldsen; Ann E Hunter; John Yin; Charles F Craddock; Inge Hoegh Dufva; Keith Wheatley; Donald Milligan
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544
  10 in total
  1 in total

Review 1.  Leukemic stem cells: identification and clinical application.

Authors:  Diana Hanekamp; Jacqueline Cloos; Gerrit Jan Schuurhuis
Journal:  Int J Hematol       Date:  2017-03-29       Impact factor: 2.490
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.